Search
for
Sort by
Research 31–60 of 1000+
- Low Free Thyroxine (FT4) in critically ill juvenile systemic lupus erythematosus: a diagnostic approach
- Oral Spironolactone for Acne Vulgaris in Adult Females: A Hybrid Systematic Review
- A novel topical combination of minoxidil and spironolactone for androgenetic alopecia: Clinical, histopathological, and physicochemical study
- Hypoactive Sexual Desire and Other Sexual Dysfunctions Caused by Side Effects of Medicines Used to Treat Various Somatic Diseases and for Contraception
- Adrenal causes of endocrine hypertension in childhood or adolescence
- Lipid nanocarriers as innovative strategies for hair regrowth
- The stag as an historical source of materia medica
- Endocrinology of Transgender Medicine
- Acne and Systemic Disease
- Persistent Sexual Dysfunction and Suicidal Ideation in Young Men Treated with Low-Dose Finasteride: A Pharmacovigilance Study
- Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients
- Female pattern hair loss: A clinical, pathophysiologic, and therapeutic review
- Ovarian Hypertension: Polycystic Ovary Syndrome
- Female Pattern Hair Loss
- Dermatological medication effects on male fertility
- Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee
- Idiopathic Hirsutism*
- Acne in the adult female patient: a practical approach
- Hidradenitis suppurativa/Acne inversa: an endocrine skin disorder?
- Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients
- Aspect-Level Drug Reviews Sentiment Analysis Based on Double BiGRU and Knowledge Transfer
- Androgens in women
- Gender-Affirming Hormone Therapy for Transgender Females
- The clinical management of hirsutism
- Obesity and the Polycystic Ovary Syndrome
- Androgen antagonists in androgen target tissues
- Hirsutism: diagnosis and treatment
- Hormone therapy in acne
- The Hirsute Woman: Challenges in Evaluation and Management
- Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies